Drug Profile
Research programme: antisense oligonucleotides - Evolve Oncology
Alternative Names: BIO123Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Evolve Oncology
- Class
- Mechanism of Action Genetic transcription inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Lung cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-cancer in USA (Inhalation)
- 19 Sep 2005 Preclinical trials in Lung cancer in USA (Inhalation)